Literature DB >> 15068436

Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro.

Seung-Heon Cha1, Jong-Soo Lee, Boo-Sup Oum, Chi-Dae Kim.   

Abstract

PURPOSE: To investigate the functional and morphological toxicity of benzalkonium chloride (BAC) on corneal epithelial cells in vitro.
METHODS: Primary corneal epithelial cells were cultured from rabbit cornea. Corneal epithelial cells containing radioactive 51Cr were exposed for 5 min, 10 min, 30 min and 60 min to concentration of BAC 0.001%, 0.005%, 0.01%, 0.05% and 0.1%. Control cells were treated with phosphate buffer solution alone. 51Cr release from epithelial cells into the supernatant was used as an index of epithelial cell lysis. Cell detachment (index of cell dysfunction) was analysed by measuring 51Cr activity in the supernatant and wash fluid. Morphological cell damage was investigated with transmission electron microscopy.
RESULTS: With the higher concentration and the longer duration of BAC exposure, corneal epithelial cell lysis was increased significantly (P < 0.05). Cells showed severe damage at BAC concentration over 0.05% during 5 min of exposure. Cell dysfunction appeared markedly at BAC concentrations of 0.005% for 30 min of exposure, but decreased with longer exposure times. There was an increase in significant cytoplasmic damage with longer BAC exposure times, although not with a minimal dose of 0.001%. Disrupted cytoplasmic membranes of corneal epithelial cells appeared at the higher BAC concentration of 0.1%, and at the longer exposure time of 30 min with BAC concentration of at least 0.001%.
CONCLUSIONS: BAC can induce corneal epithelial dysfunction, which can damage the corneal epithelial barrier. This effect occurs when BAC is used frequently or for periods over 30 min, even when the BAC concentration is low (0.001%).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068436     DOI: 10.1111/j.1442-9071.2004.00782.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  50 in total

1.  Benzalkonium Chloride Demonstrates Concentration-Dependent Antiviral Activity Against Adenovirus In Vitro.

Authors:  Eric G Romanowski; Kathleen A Yates; Robert M Q Shanks; Regis P Kowalski
Journal:  J Ocul Pharmacol Ther       Date:  2019-04-10       Impact factor: 2.671

Review 2.  Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue.

Authors:  J Javier Servat; C Robert Bernardino
Journal:  Drugs Aging       Date:  2011-04-01       Impact factor: 3.923

3.  Comparison of moxifloxacin and levofloxacin in an epithelial disorder model using cultured rabbit corneal epithelial cell sheets.

Authors:  Taku Miyake; Norihiko Ito; Kazuki Tajima; Hiroshi Goto; Toshinori Furukawa
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-27       Impact factor: 3.117

4.  NH125 kills methicillin-resistant Staphylococcus aureus persisters by lipid bilayer disruption.

Authors:  Wooseong Kim; Nico Fricke; Annie L Conery; Beth Burgwyn Fuchs; Rajmohan Rajamuthiah; Elamparithi Jayamani; Petia M Vlahovska; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  Future Med Chem       Date:  2016-02-24       Impact factor: 3.808

5.  NC-1059: a channel-forming peptide that modulates drug delivery across in vitro corneal epithelium.

Authors:  Jesica Martin; Pradeep Malreddy; Takeo Iwamoto; Lisa C Freeman; Harriet J Davidson; John M Tomich; Bruce D Schultz
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

6.  [A comparative in vitro analysis of primary and immortalized keratocytes].

Authors:  L Kagan; P W Rieck
Journal:  Ophthalmologe       Date:  2010-04       Impact factor: 1.059

7.  Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.

Authors:  Hyung Cho; Kenneth J Wolf; Eric J Wolf
Journal:  Clin Ophthalmol       Date:  2009-06-02

8.  First-year treatment costs among new initiators of topical prostaglandin analogs: pooled results.

Authors:  Jordana K Schmier; David W Covert
Journal:  Clin Ophthalmol       Date:  2010-05-14

9.  In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%.

Authors:  Abayomi B Ogundele; David Earnest; Marsha A McLaughlin
Journal:  Clin Ophthalmol       Date:  2010-07-30

10.  Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost.

Authors:  Gregory Katz; Clark L Springs; E Randy Craven; Michela Montecchi-Palmer
Journal:  Clin Ophthalmol       Date:  2010-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.